ClearPoint Neuro to Present at Stifel Virtual Healthcare 2021 Conference



SOLANA BEACH, Calif., November 04, 2021 (GLOBE NEWSWIRE) – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabled platform company providing navigation and delivery to the brain, today announced that its leadership will be presenting at the Stifel Virtual Healthcare 2021 conference on Tuesday, November 16, 2021 at 10:40 a.m. EST, by invitation only. Registration is available by contacting [email protected]

An online archive of the show will be available for 90 days on the Company’s website at www.clearpointneuro.com, on the “Investor Relations” page.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore the quality of life for patients and their families by enabling therapies for the most complex neurological disorders with pinpoint precision. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neurosuction, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint® Neuro navigation system has FDA clearance, is CE marked, and is installed at over 60 active sites in the United States, Canada and Europe. ClearPoint Neuro partners with more than 35 biologic / pharmaceutical companies and academic centers, providing solutions for the direct delivery of therapeutics to the CNS in preclinical studies and clinical trials around the world. To date, more than 4,500 cases have been completed and supported by the Company’s team of clinical specialists in the field, who provide support and services to our customers and partners around the world. For more information, please visit www.clearpointneuro.com.

Forward-looking statements

Statements contained herein concerning the plans, growth and strategies of the Company may include forward-looking statements in the context of federal securities laws. Statements regarding future events, future developments and performance of the Company, as well as management’s expectations, beliefs, plans, estimates or projections regarding the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the actual results of the Company to differ materially from those expressed or implied by forward-looking statements. Uncertainties and particular risks include those related to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, market and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; and the risks inherent in the research and development of new products. More detailed information on these and other factors that could affect the actual results of the Company are described in the section “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2020 , and in the Company’s quarterly report on form. 10-Q for the quarter ended June 30, 2021, both filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, which the Company has intends to file with the Securities and Exchange Commission no later than November 15, 2021.

CONTACT: ClearPoint Contact: Danilo D’Alessandro, Chief Financial Officer (949) 900-6833 [email protected] Caroline Corner, Investor Relations [email protected]


Previous META's intellectual property portfolio exceeds its target of 200 patents for 2021 with a total of 247 patents
Next Carbon Nanotube Industry Trends, Revenue, Size, Analysis, Key Players, Growth, Share and Forecast to 2027

No Comment

Leave a reply

Your email address will not be published.